|
1.
|
Ozols RF: Systemic therapy for ovarian
cancer: current status and new treatments. Semin Oncol. 33:S3–S11.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Rabik CA and Dolan ME: Molecular
mechanisms of resistance and toxicity associated with platinating
agents. Cancer Treat Rev. 33:9–23. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Perez RP: Cellular and molecular
determinants of cisplatin resistance. Eur J Cancer. 34:1535–1542.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Díaz-Padilla I and Poveda A: DNA
repair-based mechanisms of platinum resistance in epithelial
ovarian cancer: from bench to bedside. Clin Ovarian Cancer.
3:29–35. 2010.
|
|
5.
|
Dabholkar M, Bradshaw L, Parker RJ, Gill
I, Bostick-Bruton F, Muggia FM and Reed E: Cisplatin-DNA damage and
repair in peripheral blood leukocytes in vivo and in vitro. Environ
Health Perspect. 98:53–59. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Reed E: Platinum-DNA adduct, nucleotide
excision repair and platinum based anti-cancer chemotherapy. Cancer
Treat Rev. 24:331–344. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
De S, I, McHugh PJ, Clingen PH and Hartley
JA: Defining the roles of nucleotide excision repair and
recombination in the repair of DNA interstrand cross-links in
mammalian cells. Mol Cell Biol. 20:7980–7990. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Li Q, Yu JJ, Mu C, et al: Association
between the level of ERCC-1 expression and the repair of
cisplatin-induced DNA damage in human ovarian cancer cells.
Anticancer Res. 20:645–652. 2000.PubMed/NCBI
|
|
9.
|
Dabholkar M, Bostick-Bruton F, Weber C,
Bohr VA, Egwuagu C and Reed E: ERCC1 and ERCC2 expression in
malignant tissues from ovarian cancer patients. J Natl Cancer Inst.
84:1512–1517. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Steffensen KD, Waldstrom M, Jeppesen U,
Brandslund I and Jakobsen A: Prediction of response to chemotherapy
by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian
cancer. Int J Gynecol Cancer. 18:702–710. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Steffensen KD, Waldstrom M and Jakobsen A:
The Relationship of Platinum Resistance and ERCC1 Protein
Expression in Epithelial Ovarian Cancer. Int J Gynecol Cancer.
19:820–825. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Jiang J, Liang X, Zhou X, Huang R, Chu Z
and Zhan Q: ERCC1 expression as a prognostic and predictive factor
in patients with non-small cell lung cancer: a meta-analysis. Mol
Biol Rep. 39:6933–6942. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Hubner RA, Riley RD, Billingham LJ and
Popat S: Excision repair cross-complementation group 1 (ERCC1)
status and lung cancer outcomes: a meta-analysis of published
studies and recommendations. PLoS One. 6:e251642011. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Olaussen KA, Dunant A, Fouret P, et al:
DNA repair by ERCC1 in non-small-cell lung cancer and
cisplatin-based adjuvant chemotherapy. N Engl J Med. 355:983–991.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Kar S, Fan J, Smith MJ, Goedert M and Amos
LA: Repeat motifs of tau bind to the insides of microtubules in the
absence of taxol. EMBO J. 22:70–77. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Andre F, Hatzis C, Anderson K, et al:
Microtubule-associated protein-tau is a bifunctional predictor of
endocrine sensitivity and chemotherapy resistance in estrogen
receptor-positive breast cancer. Clin Cancer Res. 13:2061–2067.
2007. View Article : Google Scholar
|
|
17.
|
Rouzier R, Rajan R, Wagner P, et al:
Microtubule-associated protein tau: a marker of paclitaxel
sensitivity in breast cancer. Proc Natl Acad Sci USA.
102:8315–8320. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Tanaka S, Nohara T, Iwamoto M, Sumiyoshi
K, Kimura K, Takahashi Y and Tanigawa N: Tau expression and
efficacy of paclitaxel treatment in metastatic breast cancer.
Cancer Chemother Pharmacol. 64:341–346. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Shao YY, Kuo KT, Hu FC, et al: Predictive
and prognostic values of tau and ERCC1 in advanced breast cancer
patients treated with paclitaxel and cisplatin. Jpn J Clin Oncol.
40:286–293. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Mimori K, Sadanaga N, Yoshikawa Y, et al:
Reduced tau expression in gastric cancer can identify candidates
for successful Paclitaxel treatment. Br J Cancer. 94:1894–1897.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Pusztai L, Jeong JH, Gong Y, et al:
Evaluation of microtubule-associated protein-Tau expression as a
prognostic and predictive marker in the NSABP-B 28 randomized
clinical trial. J Clin Oncol. 27:4287–4292. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Pentheroudakis G, Kalogeras KT, Wirtz RM,
et al: Gene expression of estrogen receptor, progesterone receptor
and microtubule-associated protein Tau in high-risk early breast
cancer: a quest for molecular predictors of treatment benefit in
the context of a Hellenic Cooperative Oncology Group trial. Breast
Cancer Res Treat. 116:131–143. 2009. View Article : Google Scholar
|
|
23.
|
Smoter M, Bodnar L, Grala B, Stec R,
Zieniuk K, Kozlowski W and Szczylik C: Tau protein as a potential
predictive marker in epithelial ovarian cancer patients treated
with paclitaxel/platinum first-line chemotherapy. J Exp Clin Cancer
Res. 32:252013. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Kurman RJ and Shih I: Pathogenesis of
ovarian cancer: lessons from morphology and molecular biology and
their clinical implications. Int J Gynecol Pathol. 27:151–160.
2008.PubMed/NCBI
|
|
25.
|
Shih I and Kurman RJ: Ovarian
tumorigenesis: a proposed model based on morphological and
molecular genetic analysis. Am J Pathol. 164:1511–1518. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Steffensen KD, Waldstrom M, Grove A, Lund
B, Pallisgard N and Jakobsen A: Improved classification of
epithelial ovarian cancer: results of 3 Danish cohorts. Int J
Gynecol Cancer. 21:1592–1600. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Steffensen KD, Waldstrom M and Jakobsen A:
DNA-repair ERCC1 gene polymorphisms in epithelial ovarian cancer
and relation to platinum resistance and survival. J Cancer Ther.
2:140–147. 2011. View Article : Google Scholar
|
|
28.
|
Rubatt JM, Darcy KM, Tian C, et al:
Pre-treatment tumor expression of ERCC1 in women with advanced
stage epithelial ovarian cancer is not predictive of clinical
outcomes: a gynecologic oncology group study. Gynecol Oncol.
125:421–426. 2012. View Article : Google Scholar
|
|
29.
|
Bhagwat NR, Roginskaya VY, Acquafondata
MB, Dhir R, Wood RD and Niedernhofer LJ: Immunodetection of DNA
repair endonuclease ERCC1-XPF in human tissue. Cancer Res.
69:6831–6838. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Olaussen KA and Soria JC: Validation of
ERCC1-XPF immunodetection - letter. Cancer Res. 70:3851–3852. 2010.
View Article : Google Scholar : PubMed/NCBI
|
